Adequate mitomycin C can effectively reduce recurrence and progression in patients with IR NMIBC – the value of maintenance therapy*

This content has been funded by medac.

This episode explores the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC), an important topic in urology today. Expert in the field, Marco Moschini, delves into the topic of risk-adapted treatment, where patients are assigned to a particular risk group based on patient- and tumour-related factors, also taking into account the prior treatment history and the timing of recurrences.

Topics discussed include:

• Current confusion about the clinical heterogeneity within the intermediate-risk patient group
• The best way to select adequate intravesical therapy for this group
• The lack of consensus regarding an optimal schedule for adjuvant intravesical chemotherapy

*References

1. Scilipoti P, et al. Urol Oncol. 2024;42(12):451.e1-451.e10. PMID: 39060208.
2. European Association of Urology. EAU NMIBC Risk Calculator, https://nmibc.net/
3. Sylvester RJ, et al. Eur Urol. 2021;79(4):480-488. PMID: 33419683.
4. Tan WS, et al. Eur Urol Oncol. 2022;5(5):505-516. PMID: 35718695.
5. Gontero P, et al. EAU Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS), Limited Update March 2025. European Association of Urology Guidelines Office, Arnhem, The Netherlands, 2025. Full Guideline
6. Friedrich MG et al. Eur Urol. 2007;DOI:10.1016/j.eururo.2007.02.063.